Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.

RTHM-022232026Beaussant, Yvan; Sager, Zachary; Brennan, Caitlin; Kristan, Isabel; Ljuslin, Michael; Mazzola, Emanuele; Macdonald, David; Murphy, Morgan Ellasandra; Nigam, Kabir; Rinaldi, Alden D; Sanders, Justin; Schaefer, Kristen G; Sholevar, Roxanne; Summer, Lisa; Waliji-Banglawala, Alifia; Yudilevich-Espinoza, Sandra; Tulsky, James A

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.

BMJ supportive & palliative care, 16(2), 423-433

View on PubMed ↗Publisher’s paper ↗

Citation

Beaussant, Yvan; Sager, Zachary; Brennan, Caitlin; Kristan, Isabel; Ljuslin, Michael; Mazzola, Emanuele; Macdonald, David; Murphy, Morgan Ellasandra; Nigam, Kabir; Rinaldi, Alden D; Sanders, Justin; Schaefer, Kristen G; Sholevar, Roxanne; Summer, Lisa; Waliji-Banglawala, Alifia; Yudilevich-Espinoza, Sandra; Tulsky, James A. (2026). Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.. BMJ supportive & palliative care, 16(2), 423-433. https://doi.org/10.1136/spcare-2025-005773